Welcome to our dedicated page for Pulsenmore news (Ticker: PLSM), a resource for investors and traders seeking the latest updates and insights on Pulsenmore stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pulsenmore's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pulsenmore's position in the market.
Pulsenmore (NASDAQ: PLSM) began trading on Nasdaq at the U.S. market open on January 21, 2026 and will also trade on the Tel Aviv Stock Exchange. The company develops physician-supervised home prenatal ultrasound and telehealth technology combining proprietary hardware, secure cloud image transmission, and clinical review workflows.
Pulsenmore has received FDA authorization for its home-use prenatal ultrasound system, providing a regulatory foundation for potential U.S. commercialization as the company says it accelerates expansion and engagement with U.S. medical centers.